Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Achieve Life Sciences

Achieve Life Sciences Stock Has Nearly Tripled in the Last Year. Now It Just Needs to Turn a Profit.

Achieve Life Sciences (ACHV) is a $685 million biotech focused on cytisinicline-based nicotine addiction treatments, showing strong recent technical momentum. ACHV has surged 173% over 52 weeks. Shares recently hit a 3-year high earlier in July. Despite robust technicals, ACHV remains highly speculative, as it has not yet begun monetizing...

Barchart · Aug 12

FDA Set to Rule on First New Smoking Cessation Drug in 20 Years: Cytisinicline Decision Due June 20

Cytisinicline, a plant-based alkaloid for smoking cessation, has an FDA PDUFA date of June 20, 2026 — 8 days away. If approved, it would be the first new quit-smoking drug in 20 years. Phase 3 ORCA-2 and ORCA-3 trials showed significantly higher quit rates than placebo.

Medical Daily · Jun 12

Achieve Life Sciences Q1 Earnings Call Highlights

Achieve Life Sciences (NASDAQ:ACHV) used its first-quarter 2026 earnings call to outline a transition period marked by new leadership, a major financing, manufacturing changes tied to its cytisinicline regulatory timeline and preparations for a potential commercial launch in 2027. Dr. Andrew Goldbe

MarketBeat · May 12

From analysis to the latest developments in health,
read the most diverse news in one place.

4 Biotech Stocks Lifting Off As Momentum Builds

Biotech stocks have trailed the broader market this year, but more names are starting to show strength as the rally expands and major indexes reach record levels. Here's a look at four stocks showing notable momentum gains.

Benzinga · Oct 21, 2025

Achieve Life Sciences Inches Closer To FDA Nod For First New Quit-Smoking Drug In 20 Years

Achieve Life Sciences Inc. (NASDAQ:ACHV) is moving closer to a pivotal moment as it seeks FDA approval for cytisinicline, a potential first new smoking cessation therapy in nearly two decades, positioning the company for a high-stakes commercial launch in 2026.

Benzinga · Aug 21, 2025

ACHV: First Quarter 2022 Results

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga · May 13, 2022

Achieve Life Sciences: Q1 Earnings Insights

Achieve Life Sciences (NASDAQ:ACHV) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Benzinga · May 12, 2022

Read news from The Economist, FT, and more,
with one subscription

ACHV: Topline Data from ORCA-2 Smoking Cessation Trial

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT

Benzinga · May 3, 2022

Achieve Life Sciences Aces Pivotal Cytisinicline Study In Smoking Cessation

Achieve Life Sciences Inc (NASDAQ:ACHV) has announced positive topline results from the Phase 3 ORCA-2 trial of 3mg cytisinicline for 6-weeks or 12-weeks compared to a placebo in 810 adult smokers. The 6- and 12-week cytisinicline treatments demonstrated significantly better quit rates than placebo, with odds ratios of 8.0 and 6.3, respectively. Subjects…

Benzinga · Apr 27, 2022

Achieve Life Sciences: Q4 Earnings Insights

Achieve Life Sciences (NASDAQ:ACHV) reported its Q4 earnings results on Thursday, March 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga · Mar 10, 2022

Coverage From

People

John Vandermosten

46 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Achieve Life Sciences

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.